Cost-effectiveness analysis of secukinumab for the treatment of active psoriatic arthritis: a Canadian perspective

Objective: The study evaluates the cost-effectiveness of secukinumab, a fully human monoclonal antibody that selectively neutralizes interleukin (IL)-17A, vs currently licensed biologic treatments in patients with active psoriatic arthritis (PsA) from a Canadian healthcare system perspective. Method...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Journal of medical economics 2018-02, Vol.21 (2), p.163-173
Hauptverfasser:	Goeree, Ron, Chiva-Razavi, Sima, Gunda, Praveen, Graham, Christopher N., Miles, LaStella, Nikoglou, Efthalia, Jugl, Steffen M., Gladman, Dafna D.
Format:	Artikel
Sprache:	eng
Schlagworte:	biologics biosimilars Canada cost-effectiveness incremental cost effectiveness ratio (ICER) psoriatic arthritis quality-adjusted life year (QALY) Secukinumab tumor necrosis factor inhibitors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!